Kalshi and AppliedXL launch CFTC-regulated biotech prediction markets
Kalshi and public intelligence company AppliedXL launched a pilot program on Thursday, July 16, 2026, offering CFTC-regulated event contracts on clinical trial outcomes and FDA regulatory decisions. The biotech vertical marks an expansion beyond Kalshi's existing political, economic, and sports markets. Contracts will use ClinicalTrials.gov primary endpoints and official FDA outcomes as settlement benchmarks. The pilot creates publicly available probability estimates for pharmaceutical development events.
Biotech contracts give Kalshi a cleaner institutional story than flight cancellations or political markets. Hedge funds and pharma investors already price regulatory risk, so the product slots into existing workflows rather than manufacturing demand from scratch. Kalshi must still attract enough two-sided flow to keep spreads tight on low-frequency events like FDA decisions.
A thin market here would reinforce that prediction-market liquidity clusters around polarized political and sporting events. Robust volume would give Kalshi's backers a second hedging use case to cite in regulatory fights. That pressure extends to Polymarket and ForecastEx, which must match the vertical expansion or cede the institutional biotech hedging market.
Kalshi's biotech pilot joins consideration of flight cancellation markets, making healthcare and travel the newest verticals beyond politics and sports as the CFTC-regulated exchange races to prove event contracts can generate institutional hedging flow outside polarized wagering markets.